Frontline Systemic Therapy With PemetrexedPlatinum in Nonsquamous NonSmall-Cell Lung Cancer With Asymptomatic Brain MetastasesAlsidawi, Samer MD; Chaudhary, Rekha MD; Karim, Nagla A. MD, PhDAmerican Journal of Therapeutics: March/April 2017 - Volume 24 - Issue 2 - p e111–e120 doi: 10.1097/MJT.0000000000000106 Therapeutic Reviews Abstract Author Information The incidence of brain metastases from nonsquamous non–small-lung cancer is increasing as a result of superior imaging techniques for early detection of distant metastases. Although whole-brain radiation therapy and stereotactic radiosurgery along with systemic chemotherapy have shown to be effective in alleviating symptoms and improving outcomes, the approach to patients with asymptomatic brain metastases remains elusive. We explored the literature for a possible role of frontline systemic chemotherapy in asymptomatic brain metastases from nonsquamous non–small-lung cancer and found promising evidence that upfront systemic therapy with pemetrexed–platinum regimens might be a reasonable option for these patients and would forestall the need for upfront brain radiation therapy. More large-scale phase II and phase III clinical trials are needed to further investigate the frontline use of pemetrexed–platinum regimens in this setting. 1Department of Internal Medicine, University of Cincinnati, Cincinnati, OH; and 2Division of Hematology-Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH. Address for correspondence: Vontz Center for Molecular Studies, 3125 Eden Avenue, ML 0562 Cincinnati, OH 45267-0562. Phone: 513-558-2115 Fax: 513-558-2125. E-mail: email@example.com R. Chaudhary is on the advisory board for NovoTTF. The other authors have no conflicts of interest to declare. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.